Mirela Tuzovic1, Joerg Herrmann2, Cezar Iliescu3, Kostas Marmagkiolis4, Boback Ziaeian1, Eric H Yang5. 1. UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, 100 Medical Plaza, Suite 630, Los Angeles, CA, 90095, USA. 2. Division of Cardiovascular Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 3. Division of Cardiology, Department of Medicine, MD Anderson Cancer Center, University of Texas at Houston, Houston, TX, USA. 4. Pepin Heart Institute Florida Hospital, Tampa, FL, USA. 5. UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, 100 Medical Plaza, Suite 630, Los Angeles, CA, 90095, USA. ehyang@mednet.ucla.edu.
Abstract
PURPOSE OF REVIEW: Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlight the specific diagnostic and treatment considerations relevant to cancer patients. RECENT FINDINGS: Based on a recent study looking at the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of arterial thromboembolic events (ATEs) in patients with cancer at 6 months is 4.7%; the presence of an ATE is predictive of worse outcomes. Certain drugs such as platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, and taxanes have been associated with high rates of ATEs. Increased platelet reactivity appears crucial to development of arterial thrombosis in cancer patients. Cancer patients have an increased risk of arterial thrombosis that is likely due to both a cancer-associated procoagulant state as well as the adverse effects of certain chemotherapeutic agents. Treatment of arterial thromboembolism in cancer patients typically requires a multidisciplinary approach in part due to high rates of thrombocytopenia and stent thrombosis in the setting of percutaneous interventions. More studies are needed to investigate optimal prophylaxis, surveillance strategies, and treatments of cancer-related arterial thromboembolic disease.
PURPOSE OF REVIEW: Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlight the specific diagnostic and treatment considerations relevant to cancer patients. RECENT FINDINGS: Based on a recent study looking at the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of arterial thromboembolic events (ATEs) in patients with cancer at 6 months is 4.7%; the presence of an ATE is predictive of worse outcomes. Certain drugs such as platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, and taxanes have been associated with high rates of ATEs. Increased platelet reactivity appears crucial to development of arterial thrombosis in cancer patients. Cancer patients have an increased risk of arterial thrombosis that is likely due to both a cancer-associated procoagulant state as well as the adverse effects of certain chemotherapeutic agents. Treatment of arterial thromboembolism in cancer patients typically requires a multidisciplinary approach in part due to high rates of thrombocytopenia and stent thrombosis in the setting of percutaneous interventions. More studies are needed to investigate optimal prophylaxis, surveillance strategies, and treatments of cancer-related arterial thromboembolic disease.
Authors: Hege S Haugnes; Torgeir Wethal; Nina Aass; Olav Dahl; Olbjørn Klepp; Carl W Langberg; Tom Wilsgaard; Roy M Bremnes; Sophie D Fosså Journal: J Clin Oncol Date: 2010-09-20 Impact factor: 44.544
Authors: Toni K Choueiri; Fabio A B Schutz; Youjin Je; Jonathan E Rosenberg; Joaquim Bellmunt Journal: J Clin Oncol Date: 2010-03-29 Impact factor: 44.544
Authors: L S Elting; E B Rubenstein; C G Martin; D Kurtin; S Rodriguez; E Laiho; K Kanesan; S B Cantor; R S Benjamin Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: N I Weijl; M F Rutten; A H Zwinderman; H J Keizer; M A Nooy; F R Rosendaal; F J Cleton; S Osanto Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: Thomas Gremmel; Thomas Perkmann; Daniela Seidinger; Renate Koppensteiner; Simon Panzer; Christoph W Kopp; Sabine Steiner Journal: J Atheroscler Thromb Date: 2013-06-04 Impact factor: 4.928
Authors: Gillian Douglas; Erik Van Kampen; Ashley B Hale; Eileen McNeill; Jyoti Patel; Mark J Crabtree; Ziad Ali; Robert A Hoerr; Nicholas J Alp; Keith M Channon Journal: Eur Heart J Date: 2012-09-24 Impact factor: 29.983
Authors: Jose A Alvarez-Cardona; Jordan Ray; Joseph Carver; Vlad Zaha; Richard Cheng; Eric Yang; Joshua D Mitchell; Keith Stockerl-Goldstein; Lavanya Kondapalli; Susan Dent; Anita Arnold; Sherry Ann Brown; Monica Leja; Ana Barac; Daniel J Lenihan; Joerg Herrmann Journal: J Am Coll Cardiol Date: 2020-11-10 Impact factor: 24.094
Authors: Isabela Bispo Santos da Silva Costa; Fernanda Thereza de Almeida Andrade; Diego Carter; Vinicius B Seleme; Maycon Santos Costa; Carlos M Campos; Ludhmila Abrahão Hajjar Journal: Front Cardiovasc Med Date: 2021-06-09